文献速递急性肾损伤慢性肾脏病

住院镰状细胞病成人对比剂相关急性肾损伤研究

Contrast-Associated AKI in Hospitalized Adults With Sickle Cell Disease.
PubMed 文献 · Kidney Int Rep · 2026-05-14

该研究在巴黎大学医院镰状细胞病中心进行回顾性自我对照病例系列分析,纳入2013至2022年住院期间发生AKI的529名成人患者共755例AKI事件。结果显示,对比剂暴露前7天及暴露后0-3天、4-7天的AKI相对发生率均显著升高,提示AKI风险增加可能与基础临床状况及相关医疗干预有关,而非对比剂的因果效应。

要点

  • 镰状细胞病住院成人对比剂暴露前后AKI相对发生率均升高约2.5倍
  • 暴露前7天AKI发生率已升高,提示基础病情而非对比剂因果作用
  • 2或3期AKI也呈现类似模式且相对发生率更高

核心结论

  • 在主要年轻、肾功能保留且合并症少的镰状细胞病住院成人中,对比剂暴露前后AKI相对发生率均约翻倍,提示基础临床状况及相关医疗干预的作用而非对比剂因果效应。

研究设计与样本

  • 回顾性自我对照病例系列(SCCS),纳入2013至2022年巴黎大学医院镰状细胞病中心随访的住院期间发生AKI的成人患者,主要分析包含529名患者和755例AKI事件。

主要发现

  • AKI发生率在对比剂暴露前7天显著升高(RI:2.53,95%CI:2.02-3.16)。
  • AKI发生率在暴露后0至3天显著升高(RI:2.52,95%CI:1.99-3.19)。
  • AKI发生率在暴露后4至7天显著升高(RI:1.57,95%CI:1.20-2.06)。
  • 2或3期AKI呈现类似模式,且相对发生率更高。

临床怎么用

  • 对于镰状细胞病住院成人,对比剂暴露前应评估基础临床状况,AKI风险升高可能反映基础病情而非对比剂直接毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with sickle cell disease (SCD) are at risk of chronic kidney disease (CKD) and acute kidney injury (AKI). The risk of AKI associated with contrast media (CM) exposures in this population is uncertain. The objective of this study was to investigate this temporal association in a multicentric case series. METHODS: We performed a retrospective self-controlled case series (SCCS) in adults followed-up in SCD centers of the Greater Paris University Hospitals who experienced AKI during hospitalization between 2013 and 2022. SCCS estimates the relative incidence (RI) of events during exposure periods (around CM exposure) compared with control periods within the same individual. Analyses were restricted to hospitalizations periods and accounted for time-varying confounders such as age, presence of albuminuria, reduced estimated glomerular filtration rate, and stay in a medical ward or intensive care unit (ICU). RESULTS: In the main analysis, that included 529 patients and 755 cases of AKI, AKI incidence increased significantly during the 7-day pre-exposure period (RI: 2.53, 95% confidence interval [CI]: 2.02-3.16), the 0 to 3 days postexposure (RI: 2.52, 95% CI: 1.99-3.19) and the 4 to 7 days postexposure (RI: 1.57, 95% CI: 1.20-2.06). Similar patterns were observed for stage 2 or 3 AKI, with higher RI. CONCLUSION: In this cohort of hospitalized adults with SCD, mainly young patients with preserved kidney function and few comorbidities, the RI of AKI was twice as high both before and after CM exposure, suggesting the role of underlying clinical conditions and related medical interventions rather than a causal effect of CM.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Azoyan L, Lombardi Y, Bartolucci P, et al. Contrast-Associated AKI in Hospitalized Adults With Sickle Cell Disease. Kidney Int Rep. 2026. PMID: 42290906. doi:10.1016/j.ekir.2026.106600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。